Option chain shows key data for Immuron's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Immuron.

Immuron (NASDAQ:IMRN) Stock, Option Chain

Immuron

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

VFCorp.Shutterstock

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMKR

AREB

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DBGI

EVOK

FFIV

GRDI

HLIT

HRYU

IMRN

IVDA

LIXT

LTBR

QUBT

SHPH

TMDX

VEEA

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

ACOR

ADIL

ASTI

BNRG

BPTS

BSGM

CISS

DCGO

DECK

DOGZ

DXYZ

EZGO

GRRR

ICCT

IFBD

JAGX

KITT

MGAM

MRIN

MRNO

NEOV

NOVA

NUTX

OPEN

PRFX

RETO

RVMD

TSLA

VERB

VIAO

VINO

Shares of  Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6 million public offering of shares at $0.14 per share.

Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

GLMD

INAB

MSFT

PSMT

SLNA

Shares of  PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter.

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket

Immuron Limited - American Depositary Shares

Immuron Ltd

NRDY

Clover School District Teams With Varsity Tutors For Schools To Provide Comprehensive Online Tutoring Resources

Biotech

General

TEVA

Teva And Sanofi Announce Primary Endpoints Met In Phase 2b Trial Of Duvakitug  In Ulcerative Colitis And Crohn's

Offerings

EVGO

EVgo Reports Pricing Of Secondary Offering Of Class A Common Stock At $5.00 Per Share

ZENA

ZenaTech Signs LOI To Acquire A Land Survey Engineering Company; Co. Says Quantum Computing Will Be Added To AI Drone Capabilities To Accommodate Large-Size Datasets

UNCY

Unicycive Therapeutics Announces Publication Of OLC Bioequivalence Study, Supporting NDA Review And 2025 Commercial Launch

JP Morgan analyst Matthew Boss maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Neutral and raises the price target from $29 to $30.

Price Target

Analyst Ratings

NCLH

JP Morgan Maintains Neutral on Norwegian Cruise Line, Raises Price Target to $30

TNXP

Trading Halt: Halted at 7:31:17 a.m. ET - Trading Halt: Halt News Pending

Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares slipped below its short-term moving averages, indicating a potential test for its support levels near the 200-day moving averages amid CNBC&#8217;s Jim Cramer&#8216;s <a href="https://www.benzinga.com/markets/equities/24/12/42522048/jim-cramer-warns-nvidias-vicious-and-fast-reversal-is-coming-amid-174-surge-this-year-and-china-antitrust-probe">warning</a> on the semiconductor stock.
What Happened: From a technical perspective, the analysis of daily moving averages indicates that the stock may be under pressure in the short term.
The stock ended at $130.95 apiece in after-hours on Monday. This was below its eight and 20-day simple moving averages, of $138.04 and $139.83, respectively. As per <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>, its current stock price was also lower than the 50-day moving average of $139.69.
The stock was above its 200-day moving average of $115.52, which implies that it could still be in a long-term uptrend while it is testing fresh support levels near the average value.
This trend also indicates that the stock could be in a consolidation phase. On the other hand, the relative strength index of 40.18 suggests the stock is in a neutral zone and is neither overbought nor oversold.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/NVDA"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025439/Nvidia-tech-chart-1024x576.png" alt="" class="wp-image-695285" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025439/Nvidia-tech-chart-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025439/Nvidia-tech-chart-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025439/Nvidia-tech-chart-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025439/Nvidia-tech-chart-1536x864.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025439/Nvidia-tech-chart.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
See Also: <a href="https://www.benzinga.com/markets/equities/24/12/42522048/jim-cramer-warns-nvidias-vicious-and-fast-reversal-is-coming-amid-174-surge-this-year-and-china-antitrust-probe">Jim Cramer Warns Nvidia&#8217;s &#8216;Vicious&#8217; And &#8216;Fast&#8217; Reversal Is Coming Amid 174% Surge This Year And China Antitrust Probe</a>
Why It Matters: Cramer cautioned investors about Nvidia, through an X post on Monday, predicting a potential market correction for the semiconductor giant that has seen its value surge 174% this year.
"Still no crescendo moment in Nvidia. It will happen, just not yet….the reversal will be vicious though….and fast," CNBC's Cramer wrote on X, formerly Twitter, as the stock declined 1.68% to close at $132.00.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Still no crescendo moment in Nvidia. It will happen, just not yet&#8230;.the reversal will be vicious though&#8230;.and fast
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1868721912303829094?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The warning comes as Nvidia faces heightened scrutiny in China, where authorities launched an antitrust investigation last week into the company's 2020 acquisition of Mellanox Technologies.
The probe examines <a href="https://www.benzinga.com/news/legal/24/12/42404352/nvidia-china-antitrust-probe-may-remain-unsolved-in-near-term-says-top-analyst-investors-should-be-prepared-for-increased-scrutiny">potential anti-competitive practices</a>, including whether Nvidia limits competition by bundling its AI chips with Mellanox's NVLink technology.
Steven Strazza, the director of research at All Star Charts, had a contrarian view, in an X post he said, &#8220;Momentum not even close to oversold.&#8221;
He added that semiconductors are getting back in gear and the magnificent seven are making new all-time highs. As per his analysis the stock has, &#8220;Very clean and clear support level holding.&#8221;
&#8220;Only thing missing was a little shakeout, and we got it today,&#8221; he added.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">There&#39;s no way this is a top This setup in <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a> is the ideal risk-reversal pattern Very clean and clear support level holding Momentum not even close to oversold Semis getting back in gear &amp; Mag 7 making new ATHs Only thing missing was a little shakeout, and we got it today <a href="https://t.co/LxZ3RiRONp">pic.twitter.com/LxZ3RiRONp</a>
&mdash; Steven Strazza (@sstrazza) <a href="https://twitter.com/sstrazza/status/1868748780860023148?ref_src=twsrc%5Etfw">December 16, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
What Are Other Analysts Saying: TF Securities&nbsp;analyst&nbsp;Ming-Chi Kuo&nbsp;expects the investigation to remain unresolved in the near term, drawing parallels to&nbsp;Qualcomm Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) 15-month&nbsp;<a href="https://www.benzinga.com/news/legal/24/12/42404352/nvidia-china-antitrust-probe-may-remain-unsolved-in-near-term-says-top-analyst-investors-should-be-prepared-for-increased-scrutiny" target="_blank" rel="noreferrer noopener">antitrust case in China</a>.
According to <a href="https://www.benzinga.com">Benzinga</a>, Nvidia has a consensus price target of $170.56 based on the ratings of 40 analysts. The highest price target out of all the <a href="https://www.benzinga.com/quote/NVDA/analyst-ratings">analysts tracked by Benzinga</a> is $220 issued by Rosenblatt as of Nov. 21, 2024. The lowest target price is $120 issued by New Street Research on Aug. 6, 2024.
The average price target of $154.67 between DA Davidson, Phillip Securities, and Truist Securities implies an 18.11% upside for Nvidia.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/quote/NVDA/analyst-ratings"><img loading="lazy" decoding="async" width="948" height="355" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025414/Nvidia-ANR.png" alt="" class="wp-image-695278" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025414/Nvidia-ANR.png 948w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025414/Nvidia-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17025414/Nvidia-ANR-768x288.png 768w" sizes="(max-width: 948px) 100vw, 948px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/24/12/42513306/elon-musks-tesla-nearly-5-times-more-expensive-than-industry-average-stock-surges-over-60-since-election">Elon Musk&#8217;s Tesla Nearly 5 Times More Expensive Than Industry Average: Stock Surges Over 60% Since Election</a></li>
</ul>
Image via Shutterstock

Analyst Color

Equities

NVDA

QCOM

Nvidia Technical Analysis Flashes Warning As NVDA Stock Slips Below Key Moving Averages, But Analysts Still See 18.11% Upside: Here's More

SYTA

Siyata Mobile Expands Global Reach With 550-Unit Push-To-Talk Handset Order In The Netherland

Roth MKM analyst Justin Clare initiates coverage on Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) with a Buy rating and announces Price Target of $100.

Initiation

ATKR

Roth MKM Initiates Coverage On Atkore with Buy Rating, Announces Price Target of $100

STWD

Starwood Property Trust Offers $400M Of Its Unsecured Senior Notes Due 2030 In Private Offering

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Aprea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APRE#NASDAQ">APRE</a>) with a Buy and maintains $20 price target.

Reiteration

APRE

HC Wainwright & Co. Reiterates Buy on Aprea Therapeutics, Maintains $20 Price Target

JP Morgan analyst Lilia-Celine Lozada assumes Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Neutral rating and announces Price Target of $8.

TMCI

JP Morgan Assumes Treace Medical Concepts at Neutral, Announces Price Target of $8

Northland Capital Markets analyst Gus Richard initiates coverage on QuickLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUIK#NASDAQ">QUIK</a>) with a Outperform rating and announces Price Target of $11.6.

QUIK

Northland Capital Markets Initiates Coverage On QuickLogic with Outperform Rating, Announces Price Target of $11.6

UNICEPTA to join Stagwell Marketing Cloud's PRophet Comms Tech Suite

STGW

Stagwell Strengthens Global Presence With Acquisition Of UNICEPTA, Enhancing PRophet's Comms Tech Suite

AFRM: -6% &#x7C; <a href="https://www.benzinga.com//node/42517873">Affirm Holdings shares are trading lower. The company announced plans for a $750 million private offering of convertible senior notes.</a>
&nbsp;
RCAT: -18% &#x7C; <a href="https://www.benzinga.com//node/42518532">Red Cat Holdings shares are trading lower after the company reported worse-than-expected Q2 financial results.</a>
&nbsp;
PRTG: 164% &#x7C; <a href="https://www.benzinga.com//node/42526984">Portage Biotech Enters LOI With Immunova For Option To Acquire iOx Therapeutics And Lead Candidate PORT-2</a>
&nbsp;
&nbsp;

AFRM

PRTG

RCAT

Market-Moving News for December 17th

The collaboration aims to broaden access of premium medical cannabis products to Australian patients.
 &nbsp;

Aurora Cannabis Reveals Distribution Partnership Between The Entourage Effect And MedReleaf Australia

HC Wainwright &amp; Co. analyst Kevin Dede reiterates Digihost Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGHI#NASDAQ">DGHI</a>) with a Buy and maintains $2.5 price target.

DGHI

HC Wainwright & Co. Reiterates Buy on Digihost Technology, Maintains $2.5 Price Target

Mizuho analyst Gregg Moskowitz maintains Rubrik (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBRK#NYSE">RBRK</a>) with a Outperform and raises the price target from $75 to $82.

RBRK

Mizuho Maintains Outperform on Rubrik, Raises Price Target to $82

JP Morgan analyst Lilia-Celine Lozada assumes AtriCure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRC#NASDAQ">ATRC</a>) with a Overweight rating and announces Price Target of $40.

ATRC

JP Morgan Assumes AtriCure at Overweight, Announces Price Target of $40

Aptevo Therapeutics, Immuron, CASI Pharmaceuticals among healthcare movers

Lexicon Pharmaceuticals, Mesoblast, Ventyx Biosciences among healthcare movers

Immuron ADR (IMRN) is near the bottom in its sector according to InvestorsObserver.IMRN gets an overall rating of 0. That means it scores higher than 0% of stocks.Immuron ADR gets a 0 rank in the Healthcare sector. Healthcare is number 1 out of 11 sectors. IMRN has an Overall Score of 0. Find out what this means to you and

Will Immuron ADR (IMRN) Trail the Rest of the Stocks in the Healthcare Sector?

ELTK, PSTX and LTRN among mid-day movers

Immuron gains after Travelan sales update

Immuron to raise up to $2M as part of an ATM equity offering

Immuron (IMRN) has released an update. Immuron Limited's CEO, Steven Lydeamore, is set to present at the Sharewise conference on July 9, 2024, disc...

Immuron CEO to Unveil Company Progress at Sharewise

Immuron (IMRN) has released an update. Immuron Limited has announced a significant surge in global sales of its Travelan&#xAE; product, with a record in...

Immuron's Travelan® Hits Record Global Sales

Immuron (IMRN) has released an update. Immuron Limited reported a significant increase in revenue, up 171.7% to $4.9 million for the year ended Jun...

Immuron Sees Revenue Surge Amid Higher R&D Costs

Immuron (IMRN) has disclosed a new risk, in the Accounting & Financial Operations category. Immuron faces a substantial business risk if it fails t...

Immuron's Compliance Crucial: Sarbanes-Oxley Act Adherence Key to Financial Stability and Investor Trust

AIMD

AMIX

APVO

BALY

CASI

CERO

ELTK

ENCP

GRPH

GRYP

JFBR

JRVR

LBBB

LTRN

LXRX

MEDS

MESO

MRAI

PSTX

TCBP

VTYX

Press Releases

Presenting on the Emerging Growth Conference 75 Day 1 on September 25 Register Now

Presenting on the Emerging Growth Conference 75 Day 2 on September 26

NMRC Reports Results for Campylobacter Controlled Human Infection Model Study

Health Care

Immuron Travelan® continued strong sales growth

Immuron CEO, Steven Lydeamore participation in Maxim Virtual Healthcare Conference

Presenting on the Emerging Growth Conference 76 Day 1 on October 30 Register Now

Presenting on the Emerging Growth Conference 76 Day 2 on October 31 Register Now

Events

Immuron Limited to Present at November 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore presentation to 21st Virtual Investor Summit Microcap Event

Immuron CEO, Steven Lydeamore to Present at the Small Cap Growth Virtual Investor Conference December 5th

Comments

Immuron

Immuron (IMRN) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga